Altamira Therapeutics EBIT

The latest EBIT for CYTO is $-2.6M as of June 2023. That compares with $-7.3M in the prior-year period — up 64.2% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Altamira Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CYTO's EBIT moved from $-7.3M to $-2.6M — a 64.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Altamira Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, CYTO currently prints $-2.6M for EBIT, while the sector average sits near $23B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Altamira Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-2.6M for CYTO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting CYTO's EBIT ($-2.6M), review year-over-year change from $-7.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.